# Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

> **NCT05757466** · PHASE2 · UNKNOWN · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Prolgolimab
- **DRUG:** Combination with prolgolimab and bendamustine

## Key facts

- **NCT ID:** NCT05757466
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-19
- **Primary completion:** 2024-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757466, "Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05757466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*